Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 387, Issue 7, Pages 663-664Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc2207889
Keywords
-
Categories
Ask authors/readers for more resources
The study demonstrates that active treatment for mild chronic hypertension in pregnant women leads to better outcomes compared to treating only severe hypertension, without increasing adverse fetal outcomes. Based on the data, withdrawal of labetalol may be necessary to achieve the observed blood pressure difference between the trial groups.
To the Editor: In their article on the Chronic Hypertension and Pregnancy (CHAP) trial, Tita et al. (May 12 issue)(1) report better pregnancy outcomes in women assigned to active treatment of mild chronic hypertension (blood-pressure goal, <140/90 mm Hg) than in those assigned to treatment only for severe hypertension, with no increase in adverse fetal outcomes. We infer from data in Tables S2 and S4 in the Supplementary Appendix (available with the full text of the article at NEJM.org) that in order to achieve the observed difference in blood pressure between the trial groups, labetalol was withdrawn in at least . . .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available